Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Cue Biopharma, Inc.NASDAQ: CUE
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit growth accelerates
Q1 FY2026 gross profit of $5.69M rose 1250.6% year over year, ahead of the +308.6% change in trailing-twelve-month gross profit. Sequentially, it fell 74.1% from the prior quarter. Over 3 fiscal years it compounded at +180.5% a year.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1250.6% holds above the trailing-twelve-month pace of +308.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 27.47M USD
- Year-over-year change
- +195.7%
- 4-year CAGR
- +13.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.47M | +195.7% |
| FY2024 | 2024-12-31 | 9.29M | +128.5% |
| FY2023 | 2023-12-31 | (32.61M) | -2719.0% |
| FY2022 | 2022-12-31 | 1.25M | -92.6% |
| FY2021 | 2021-12-31 | 16.72M | — |
Gross Profit vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's LTM Mar 2026 gross profit of $32.65M is the highest of the 7 companies compared; the peer median is -$39.5K.
- Its year-over-year change of +308.6% is the 3rd highest of 7, against a peer median of -100.1%.
- Gross profit amounts to 99.8% of revenue for CUE, versus a peer median of 87.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.65M | +308.6% | +180.5% | 99.8% | |
| LTM Mar 2026 | $1.23M | +6860.8% | — | 87.2% | |
| LTM Mar 2026 | $851K | +21375.0% | — | 37.1% | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | -$79K | -100.3% | — | — | |
| LTM Mar 2026 | -$1.2M | -4457.3% | — | 360.9% | |
| LTM Mar 2026 | -$29.86M | -126.0% | +164.4% | — | |
| Peer median (excluding CUE) | -$39.5K | -100.1% | +164.4% | 87.2% | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.94M | 1.25M | 5.49M | 9.29M | 27.47M |
| Cost of Revenue | (1.78M) | 0 | 38.1M | 0 | 0 |
| Gross Profit | 16.72M | 1.25M | (32.61M) | 9.29M | 27.47M |
| Gross Margin | 111.9% | 100.0% | -593.9% | 100.0% | 100.0% |
| Research & Development | 41.35M | 38.58M | 40.8M | 36.3M | 37.74M |
| Selling, General & Admin | 17.31M | 16.17M | 16.68M | 14.59M | 16.24M |
| Operating Expenses | 60.43M | 54.47M | 19.54M | 50.79M | 53.99M |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 3.48M |
| EBITDA | (45.44M) | (50.49M) | (46.05M) | (37.53M) | (22.27M) |
| EBITDA Margin | -304.1% | -4055.5% | -838.8% | -404.1% | -81.1% |
| Operating Income | (43.71M) | (53.23M) | (52.15M) | (41.5M) | (26.52M) |
| Operating Margin | -292.6% | -4275.1% | -949.9% | -446.9% | -96.6% |
| Interest Income | 45.9K | 928.24K | 2.66M | 1.62M | 807K |
| Interest Expense | 0 | 713.82K | 1.25M | 796K | 357K |
| Other Income / Expenses | 45.9K | 215K | 1.42M | 826K | 419K |
| Income Before Tax | (43.67M) | (53.01M) | (50.73M) | (40.67M) | (26.1M) |
| Pre-Tax Margin | -292.3% | -4257.8% | -924.1% | -438.0% | -95.0% |
| Income Tax Expense | 495K | 0 | 0 | 0 | 500K |
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Net Margin | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
| EPS (Basic) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| EPS (Diluted) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| Weighted Avg Shares | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
| Weighted Avg Shares (Diluted) | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.